S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NYSE:IQV

IQVIA Stock Forecast, Price & News

$180.34
-2.68 (-1.46 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$180.06
Now: $180.34
$184.68
50-Day Range
$167.30
MA: $180.70
$191.44
52-Week Range
$81.79
Now: $180.34
$192.34
Volume740,586 shs
Average Volume821,160 shs
Market Capitalization$34.58 billion
P/E Ratio198.18
Dividend YieldN/A
Beta1.41
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQVIA logo

MarketRank

Overall MarketRank

1.87 out of 5 stars

Business Services Sector

48th out of 442 stocks

Commercial Physical Research Industry

2nd out of 42 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
CUSIPN/A
Phone919-998-2000
Employees67,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.09 billion
Cash Flow$11.79 per share
Book Value$32.28 per share

Profitability

Net Income$191 million

Miscellaneous

Market Cap$34.58 billion
Next Earnings Date2/10/2021 (Estimated)
OptionableOptionable
$180.34
-2.68 (-1.46 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IQVIA (NYSE:IQV) Frequently Asked Questions

How has IQVIA's stock price been impacted by COVID-19?

IQVIA's stock was trading at $125.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 43.8% and is now trading at $180.34.
View which stocks have been most impacted by COVID-19
.

Is IQVIA a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IQVIA stock.
View analyst ratings for IQVIA
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IQVIA?

Wall Street analysts have given IQVIA a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IQVIA wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Ari Bousbib's approval rating as IQVIA's CEO?

1,545 employees have rated IQVIA CEO Ari Bousbib on Glassdoor.com. Ari Bousbib has an approval rating of 84% among IQVIA's employees.

When is IQVIA's next earnings date?

IQVIA is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for IQVIA
.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) posted its earnings results on Tuesday, October, 20th. The medical research company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. The medical research company earned $2.79 billion during the quarter, compared to analysts' expectations of $2.75 billion. IQVIA had a trailing twelve-month return on equity of 18.03% and a net margin of 1.61%. IQVIA's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.60 earnings per share.
View IQVIA's earnings history
.

What price target have analysts set for IQV?

17 brokerages have issued 1-year target prices for IQVIA's shares. Their forecasts range from $110.00 to $224.00. On average, they anticipate IQVIA's stock price to reach $173.94 in the next year. This suggests that the stock has a possible downside of 3.5%.
View analysts' price targets for IQVIA
or view Wall Street analyst' top-rated stocks.

Who are some of IQVIA's key competitors?

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQVIA investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), PayPal (PYPL), salesforce.com (CRM) and Accenture (ACN).

Who are IQVIA's key executives?

IQVIA's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 60, Pay $8.93M)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $1.11M)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 58, Pay $1.38M)
  • Mr. Kevin C. Knightly, Pres of Technology & Commercial Solutions (Age 60, Pay $1.18M)
  • Mr. Ronald E. Bruehlman, Exec. VP & Interim CFO (Age 60)
  • Mr. Emmanuel N. Korakis, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 47)
  • Dr. Jeffrey A. Spaeder, Sr. VP, Global Chief Medical & Scientific Officer
  • Mr. Alejandro Martinez, Chief Information Officer
  • Andrew Markwick, Sr. VP of Investor Relations & Treasury
  • Ms. Trudy Stein, Chief HR Officer & Exec. VP

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are IQVIA's major shareholders?

IQVIA's stock is owned by a number of institutional and retail investors. Top institutional investors include Ardevora Asset Management LLP (0.18%), Lateef Investment Management L.P. (0.16%), Strs Ohio (0.13%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.13%), Retirement Systems of Alabama (0.12%) and Veracity Capital LLC (0.11%). Company insiders that own IQVIA stock include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for IQVIA
.

Which institutional investors are selling IQVIA stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Exchange Traded Concepts LLC, Strategic Blueprint LLC, Pacer Advisors Inc., UNIVEST FINANCIAL Corp, State of Alaska Department of Revenue, First Hawaiian Bank, and Gradient Investments LLC. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Ronald A Rittenmeyer.
View insider buying and selling activity for IQVIA
or view top insider-selling stocks.

Which institutional investors are buying IQVIA stock?

IQV stock was bought by a variety of institutional investors in the last quarter, including Clark Capital Management Group Inc., DNB Asset Management AS, Veracity Capital LLC, Lateef Investment Management L.P., Kestra Advisory Services LLC, Ardevora Asset Management LLP, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, and Vision Capital Management Inc.. Company insiders that have bought IQVIA stock in the last two years include John G Danhakl, and Ronald E Bruehlman.
View insider buying and selling activity for IQVIA
or or view top insider-buying stocks.

How do I buy shares of IQVIA?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $180.34.

How big of a company is IQVIA?

IQVIA has a market capitalization of $34.58 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. IQVIA employs 67,000 workers across the globe.

What is IQVIA's official website?

The official website for IQVIA is www.iqvia.com.

How can I contact IQVIA?

IQVIA's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.